Department of Physiology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran; Department of Physiology, Bam University of Medical Sciences, Bam, Iran.
Neuroscince and Endocrinology and Metabolism Research Centers, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Biochem Pharmacol. 2020 Aug;178:114044. doi: 10.1016/j.bcp.2020.114044. Epub 2020 May 21.
Several studies have shown that 17β-estradiol (E2) exerted beneficial effects on liver disease, and it has a protective impact on brain damage after traumatic brain injury (TBI). TBI-induced liver injury is associated with the activation of TLR4. However, it remains unknown whether E2 can modulate TBI-induced liver injury through TLR4. The objective of this study was to determine the role of TLR4 in hepatoprotective mechanisms of E2 after TBI. Diffuse TBI induced by the Marmarou model in male rats. TAK-242 as a selective antagonist of TLR4 (3 mg/kg) and E2 (33.3 μg/kg) were injected (i.p) respectively 30 min before and 30 min after TBI. The results showed that E2 and TAK-242 markedly inhibited TBI-induced liver injury, which was characterized by decreased aminotransferase activities, inhibition of the oxidative stress, and reduced levels of pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and IL-17 in the liver. We also found that TBI induced significant upregulation of TLR4 in the liver, with peak expression occurring 24 h after TBI, and that treatment with E2 significantly inhibited the upregulation of TLR4. Also, both classic [Estrogen receptors alpha (ERα) and beta (ERβ)] and non-classic (G protein-coupled estrogen receptor GPER) E2 receptors are involved in modulating the expression of TLR4. These results suggested that the hepatoprotective effects of estradiol after TBI may be mediated via the downregulation expression of TLR4.
几项研究表明,17β-雌二醇(E2)对肝脏疾病有有益的影响,并且对创伤性脑损伤(TBI)后的脑损伤有保护作用。TBI 诱导的肝损伤与 TLR4 的激活有关。然而,E2 是否可以通过 TLR4 调节 TBI 诱导的肝损伤尚不清楚。本研究旨在确定 TLR4 在 E2 对 TBI 后肝保护机制中的作用。雄性大鼠采用 Marmarou 模型诱导弥漫性 TBI。TLR4 的选择性拮抗剂 TAK-242(3mg/kg)和 E2(33.3μg/kg)分别于 TBI 前 30min 和 TBI 后 30min 腹腔注射。结果表明,E2 和 TAK-242 明显抑制 TBI 诱导的肝损伤,表现为转氨酶活性降低、氧化应激抑制以及肝内促炎细胞因子肿瘤坏死因子-α(TNF-α)和 IL-17 水平降低。我们还发现,TBI 诱导肝内 TLR4 显著上调,TBI 后 24h 达到峰值,E2 治疗显著抑制 TLR4 的上调。此外,经典 [雌激素受体 alpha(ERα)和 beta(ERβ)] 和非经典(G 蛋白偶联雌激素受体 GPER)E2 受体都参与调节 TLR4 的表达。这些结果表明,E2 对 TBI 后肝脏的保护作用可能是通过下调 TLR4 的表达来介导的。